University of Oxford’s potential COVID-19 vaccine has been licensed to AstraZeneca. According to sources, positive news on the initial trials of the vaccine could be announced today, said ITV’s political editor Robert Peston.
The potential vaccine is in phase-3 of the clinical trials. The assessment is taking place in a large-scale to check whether the vaccine could fight against the Coronavirus. But its developers are yet to report the phase-1 results which would show whether it is safe to and induces an immune response.
Seeing the immune response in the trails so far, the developers were encouraged to publish the data by the end of July. It is expected to be published by The Lancet medical journal.
Over 100 vaccines are being developed and tested around the world to fight against the Coronavirus infection, which has affected millions of people and taken hundreds of thousands of lives.
The World Health Organisation (WHO) Chief Scientist said in June that AstraZeneca’s experimental vaccine is probably the leading vaccine candidate in the world and the most advanced in terms of development.
Should the vaccine be cleared for use, it will be supplied around the globe to use, as per the agreement signed by the company.
On Tuesday, researchers in the United States reported that Moderna Inc’s experimental vaccine showed positive outcomes and provoked an immune response in all 45 volunteers in an ongoing study.
